Yahoo
    Paris - Delayed Quote EUR

    Valerio Therapeutics Société anonyme (ALVIO.PA)

    0.4275 +0.0045 (+1.06%)
    As of 12:49:29 PM GMT+1. Market Open.
    Loading Chart for ALVIO.PA
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic

    Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic
    Business Wire 22d ago
    Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition

    Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition
    Business Wire 2mo ago
    Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update

    Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update
    Business Wire 3mo ago
    Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines

    Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines
    Business Wire 4mo ago
    Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting

    Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
    Business Wire 4mo ago
    Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

    Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026
    Business Wire 27d ago
    Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors

    Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
    Business Wire 2mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: